Tillotts Pharma is specialized in the treatment of diseases of the gastrointestinal tract. The focus is on chronic inflammatory bowel diseases such as Crohn’s disease, ulcerative colitis, microscopic colitis and a product for the preparation of colonoscopy. Tillotts is a competent and reliable partner for the health of the digestive system and develops innovative solutions to improve the quality of life of patients.
Tillotts Pharma GmbH, located in Berlin and Rheinfelden (Baden), is a subsidiary of the Swiss Tillotts Pharma AG. More than 300 employees worldwide coordinate the development and production, in- and out-licensing as well as the marketing of drugs and therapy solutions via partners and own subsidiaries in more than 65 countries. Tillotts is part of the Japanese pharmaceutical group Zeria. Further information can be found at www.tillotts.de and www.zeria.co.jp/english
Project description: We have been supporting Tillotts Pharma GmbH in corporate communications since the start of sales activities in Germany in 2017.
Project duration: January 2017 until today
News: Please see the website www.tillotts.de/news-events